Aubreville, Marc, Ammeling, Jonas, Banerjee, Sweta, Weiss, Viktoria, Donovan, Taryn A., Klopfleisch, Robert, Lv, Jiaqi, Raza, Shan E Ahmed, Bourgade, Raphaël, Walter, Thomas, Topuz, Yasemin, Varlı, Songül, Collins-Fekete, Charles-Antoine, Shen, Zhuoyan, Kelam, Navya Sri, Singhal, Nitin, Marzahl, Christian, Napora, Brian, Xu, Tengyou, Gu, Hongyan, Vento, Mario, Percannella, Gennaro, Ropiak, Norbert, Wasiak, Izabela, Xiao, Jie, Liu, Shaojun, Choe, Seungho, Khademi, April, Walia, Vidushi, Kotte, Sujatha, Broad, Andrew, Wright, Alex, Balezo, Guillaume, Nasir, Esha Sadia, Jahanifar, Mostafa, Yamagishi, Yosuke, Hanaoka, Shouhei, Sarno, Mattia, Tortorella, Francesco, Meng, Biwen, Liu, Jingxin, Krauss, Sara, Hieber, Daniel, Ramchandani, Lavish, Das, Dev Kumar, Ochi, Mieko, Bae, Yuan, Giedziun, Piotr, Maniewski, Mateusz, Saipradeep, Vangala Govindakrishnan, Sivadasan, Naveen, Benito-Del-Valle, Leire, Galdran, Adrian, Atey, Kaustubh, Jha, Sameer Anand, Dukre, Adinath, Razzak, Imran, Lafarge, Maxime W., Koelzer, Viktor H., Porsche, Nils, Stathonikos, Nikolas, Veta, Mitko, Hirling, Dominik, Iván, Zsanett Zsófia, Horvath, Peter, Breininger, Katharina, Bertram, Christof A.
Abstract
Automated mitosis detection is a well-established task in computational pathology. While previous benchmarks focused on scanner-induced domain shift, clinical "real-world" application requires models to be robust across the vast variance to be expected in the histological landscape. The MItosis DOmain Generalization (MIDOG) 2025 challenge was designed to evaluate algorithmic performance across unprecedented biological and contextual diversity. We curated a test dataset of 365 cases, encompassing 12 distinct human, canine and feline tumor types, digitized across multiple scanning platforms. Moving beyond hand-selected hotspots, the challenge required detection also in random tissue areas (representative of the whole slide detection situation) and challenging areas (areas rich in hard negatives). In the second track, we introduced the classification of atypical mitotic figures (AMFs). There were 18 teams submitting to the detection track, with F1 scores ranging up to 0.740. In the AMF detection track, we had 21 submissions with balanced accuracy values up to 0.908. Our analysis reveals that while most models perform reliably in traditional hotspots, significant performance degradation occurs in challenging ROIs, where false positive rates tripled. Furthermore, performance varied significantly across the 12 tumor types, highlighting "blind spots" in current state-of-the-art architectures when encountering rare or highly pleomorphic malignancies. Moreover, we evaluated the effectiveness of ensembling and found a mean increases of 1.5 and 1.3 percentage points in F1 score and balanced accuracy, respectively. In contrast, TTA showed no relevant improvement. MIDOG 2025 demonstrates that "in the wild" mitosis detection remains a significant hurdle. The transition from hotspot-only evaluation to a multi-contextual framework provides a more realistic proxy for clinical reliability.
Chinese Translation
自动化有丝分裂检测是计算病理学中一个成熟的任务。尽管以往的基准测试集中于扫描仪引起的领域转移,但临床“真实世界”应用要求模型在组织学景观中预期的广泛变异中保持稳健。MItosis DOmain Generalization (MIDOG) 2025挑战旨在评估算法在前所未有的生物和情境多样性下的表现。我们策划了一个包含365个病例的测试数据集,涵盖12种不同的人类、犬类和猫类肿瘤类型,且在多个扫描平台上进行了数字化。挑战不仅要求在手动选择的热点区域进行检测,还要求在随机组织区域(代表整个切片检测情况)和具有挑战性的区域(富含难以检测的负样本的区域)进行检测。在第二个赛道中,我们引入了对非典型有丝分裂细胞(AMFs)的分类。共有18个团队提交了检测赛道的作品,F1分数最高达到0.740。在AMF检测赛道中,我们收到了21份提交,平衡准确率最高达到0.908。我们的分析显示,尽管大多数模型在传统热点区域表现可靠,但在具有挑战性的感兴趣区域(ROIs)中,性能显著下降,假阳性率增加了三倍。此外,不同肿瘤类型的性能差异显著,突显了当前最先进架构在遇到稀有或高度多形性恶性肿瘤时的“盲点”。此外,我们评估了集成方法的有效性,发现F1分数和平衡准确率分别平均提高了1.5和1.3个百分点。相比之下,TTA未显示出相关的改善。MIDOG 2025表明,“野外”有丝分裂检测仍然是一个重大挑战。从仅评估热点区域到多情境框架的过渡,为临床可靠性提供了更现实的代理。